Our People

Hari Kumar, PhD Director


Hari Kumar is an entrepreneurial Pharmaceutical executive with over 25 years of experience in the industry. Hari started his Pharmaceutical career at Roche in basic research, subsequently moving to sales and marketing, lifecycle management, and finally to business development. From 1996 through 1999, Hari was the European Marketing Director for Eisai Ltd before returning to Roche in 1999 as Global Head of Transplant Immunosuppressives. He moved to Amira Pharmaceuticals Inc in 2007 as Chief Business Officer and after Amira’s acquisition in 2011, was Chief Executive Officer of Panmira Pharmaceuticals LLC for two years. In 2013 Hari became Chief Executive Officer of Adheron Therapeutics, Inc which he led until the successful acquisition of the company by Roche in 2015. Hari has overseen the launch of the immunosuppressive, CellCept®, the Alzheimer’s drug, Aricept® and the gastric ulcer drug, Aciphex®. He also guided cross-functional teams at Roche for the Transplantation franchise which resulted in the growth of the franchise sales into the billions of dollars. When leading inflammation in-licensing at Roche, he identified and partnered valuable products that have enhanced Roche’s portfolio. He was instrumental in partnerships with Isotechnika, Biotie, Biocryst, and Actelion. Experience in almost all aspects of the pharmaceutical industry has given Hari a unique understanding on what makes a successful pharmaceutical business.

At Amira, Hari led the process that resulted in the acquisition by Bristol Myers Squibb in 2011. His second big acquisition came as CEO and Board member of Adheron Therapeutics, Inc, which was bought by Roche. He has now led two acquisitions which have resulted in over a billion dollars in returns to investors. Hari trained as an immunologist at University College London where he completed his PhD under the supervision of Prof N A Mitchison. Hari completed a postdoctoral fellowship at Tufts New England Medical Center in Boston and another fellowship at the Marie Curie Cancer Research Centre in UK.


Back to All